Express Pharma

Biosynth Carbosynth and Shengquan acquire new plant to increase production capacities in China

The expansion, through a further production site, now allows the group more flexibility and larger production volumes together with an increased production reliability

0 245

Biosynth Carbosynth and Jinan Shengquan Group announced their acquisition of Kexing Biopharmaceutical’s raw material factory in Jinan, China. With this acquisition, Biosynth Carbosynth’s and Shengquan’s joint venture Carbotang expands the production capacities significantly. The more than 30,000-square metre property contains a comprehensive factory building on five floors, a demo workshop and a large warehouse including a state-of-the-art dangerous material storage. The expansion, through a further production site, now allows the group more flexibility and larger production volumes together with an increased production reliability. This is an essential prerequisite in the production of Biosynth Carbosynth’s products.

Speaking in this regard, Dr Urs Spitz, CEO, Biosynth Carbosynth, said, “We are delighted to be further expanding our manufacturing operations and joint venture. With this strategic acquisition, we can continue to deliver our enormous range of products at increasing scales, with unrivalled expertise in complex organic chemistries.”

- Advertisement -

Leave A Reply

Your email address will not be published.